knowledge -WSS

knowledge

author：comprehensive 2025-09-29 18:17:21 - browse：1165

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. — Scott Olson/Getty Images

WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.

The negotiated prices won’t take effect until 2026.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout Newsletter: XBI biotech index, Akero Therapeutics

WSS

CVS is willing to dump 10% of its Medicare Advantage members

Readout Newsletter: What happened with Sarepta's Duchenne data

Emergency medicine has repudiated 'excited delirium.' Now what?

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

As H5N1 spreads in cows, experts warn against drinking raw milk

Traditional Chinese medicine benefits explored in new JAMA study

leisure time

knowledge

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Abbott's new stent may help patients with peripheral artery disease

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biden's order seeks to regulate AI risk without stifling innovation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cassava reveals details — and problems — with Alzheimer's study

Drug repurposing or repositioning? The language matters

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Tori Bowie and the unacceptable rates of Black maternal death

Obesity drug from Roche shows promise in early study

entertainment

Abbott's new stent may help patients with peripheral artery disease

Testing for cancer recurrence creates a new limbo for patients

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Testing for cancer recurrence creates a new limbo for patients

Cassava reveals details — and problems — with Alzheimer's study

ALS treatment from Biogen, Ionis fails in study

leisure time

entertainment

leisure time

focus